A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors
NCT07020221 · RECRUITING · Phase 2
We track 1 ClinicalTrials.gov studies led by Verastem Inc. The portfolio skews toward Phase 2 (1 trials).
1 clinical trials sponsored by Verastem Inc.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
Verastem Inc currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 2.
Verastem Inc conducts research across multiple therapeutic areas. Browse the trial listings for details.
Yes, Verastem Inc currently has 1 trial that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.